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the condition/controls (employees without condition) were: BPD 239/85,420; OMD 
5508/76,372; CC 920/143,287; FD 918/143,138; GERD 6172/133,466; gout
600/123,461; and insomnia 7951/134,094. All incremental SL cost differences
were signiﬁ cant (P  0.05). From highest to lowest, the incremental annual SL costs 
(condition-control) were: gout  $359(172.5% higher than controls), insomnia
 $208(162.1%), OMD  $175(142.4%), GERD  $169(141.1%), CC 
$127(133.8%), FD  $120(128.8%), BPD  $94(119.7%). From highest to lowest, 
the incremental annual absence days were: gout  2.8(178.3% of control), OMD 
2.3(186.9%), BPD  1.9(157.0%), insomnia  1.6(175.4%), GERD  1.3(141.5%),
FD  0.8(126.7%), and CC  0.7(130.5%). CONCLUSIONS: Employees with insom-
nia, FD, GERD, gout, CC, BPD, and OMD incur more absences and costs than
employees without these conditions, suggesting that management of these conditions 
should focus on both the workplace and health care settings. Because individual sala-
ries were used to calculate the costs for each condition, the differences in the ordering
of the incremental days and payments may be attributable to job-related differences
between the diseases. Gout had the highest incremental costs and days of any of the 
studied conditions.
PHP51
DOES IMPROVING QUALITY OF CARE SAVE MONEY? ANALYSIS OF
HEALTH CARE EFFECTIVENESS DATA AND INFORMATION SET (HEDIS)
MEASURES
Broder MS1, Ory C1, Yermilov I2, Ko C2, Maggard MA2, Keeler EB3
1Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA, 2UCLA Center for 
Surgical Outcomes and Quality, Los Angeles, CA, USA, 3RAND Health, Santa Monica, CA, 
USA
OBJECTIVES: To determine whether improving quality of care saves money we
examined costs and beneﬁ ts of increasing compliance with the 2006 Healthcare
Effectiveness Data and Information Set (HEDIS) measures. METHODS: We systemati-
cally reviewed English-language scientiﬁ c literature (1998–2008) for US or Western
European cost effectiveness analyses published as original articles that compared
HEDIS-compliance to non-compliance and reported cost and beneﬁ ts. We abstracted 
costs, effectiveness, and incremental cost effectiveness ratios (ICER). Using US Census 
data, we calculated the total annual cost and beneﬁ t associated with moving from
2006 HEDIS rates to 95% compliance. RESULTS: We screened 1641 articles, reviewed 
222, and accepted 18 (relating to 19 of 25 measures). Greater compliance with 6 
measures reduced costs. Increasing compliance with the remaining 13 measures
increased costs but improved health; ICERs varied from $180/quality-adjusted-life-
year (QALY) (initiation of alcohol/drug treatment) to $39,805/QALY (breast cancer
screening). The number of people required to reach 95% compliance varied from 0
for beta-blocker use after MI (2006 compliance 96.6%) to 39 million for ﬂ u shots 
(2006 compliance 44.5%%). The most costly measure was comprehensive diabetes 
care ($7 billion/year) and the least costly were increasing childhood immunizations 
and reducing inappropriate imaging studies for back pain (each saving almost $400 
million/year). 95% compliance on all measures would cost $13.2 billion annually, save
$1 billion (net $12.2 billion), and add 7 million QALYs for a mean overall cost effec-
tiveness of under $2000/QALY. CONCLUSIONS: Improving quality using a nation-
ally accepted list of quality measures would increase, not reduce, costs. A published
study estimated that recent medical advances have improved health at a cost of $30–
$85,000/QALY; in comparison, improving compliance with HEDIS measures may be
an attractive investment. If more HEDIS measures examined overuse (e.g. of treat-
ments with inadequate evidence of effectiveness), improving compliance with the entire
set might reduce costs.
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OBJECTIVES: Uncertain decisions made using a cost-effectiveness threshold applied 
to each decision problem separately fail to identify the true opportunity costs of displac-
ing other unrelated programmes. We show that the allocation problem can be charac-
terised to provide a more general and comprehensive approach to informing adoption 
and research decisions. METHODS: A stochastic mathematical programming approach
is used to solve the allocation problem. The formulation allows the characterisation of 
actual budgetary policies, including a strict budgetary rule where deﬁ cits are not pos-
sible and constraints must always be met. The opportunity costs (health forgone due 
to curtailing some programmes and treatments) of violating the budget constraint are 
incorporated directly. In addition, the value of acquiring new evidence to inform the
allocation problem in light of its current uncertainty is considered simultaneously and 
consistently. RESULTS: The allocation and research decision problem depends on a 
number of considerations: 1) size of overall budget; 2) budgetary policy in place; 3)
information that is revealed and its timing; 4) subsequent actions available to decision
makers; and 5) costs of effectively monitoring ex-ante plans. Standard decision rules 
in cost-effectiveness analysis are only optimal under very special circumstances, which 
require budget constraints to be soft in addition to assumptions of perfect divisibility,
constant returns and all costs and beneﬁ ts occurring within the budgetary period.
However, if the budget constraint is hard then technologies will need to be more cost-
effective (an incremental cost-effectiveness ratio substantially below the threshold)
before the decision maker should take the risk of an ex-ante decision to adopt them. 
CONCLUSIONS: Standard decision rules and measures of value are proxies for an 
uncertain and complex process. There are no simple ex-ante decision rules in most
common circumstances and the value of information cannot be established for one 
programme independently of the rest of the allocation problem.
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OBJECTIVES: Reimbursement for the same drug may differ with respect to channel
of distribution. The objective of this study was to assess differences in reimbursement 
per unit of product dispensed and to compare pharmaceutical expenditures between 
mail-order and community pharmacy. METHODS: Pharmacy claims from a retire-
ment system for the period 2000–2005 were used in the analysis. Differences in reim-
bursement per unit of product dispensed and expenditures were estimated using a 
basket of drug items (i.e. unique combinations of drug products, formulations, 
strength, and generic status) dispensed in both channels. Rebates were not included 
in the analysis. Differences were assessed using bootstrapped 90% percentile and 
hybrid conﬁ dence intervals. RESULTS: The comparison basket contained 1,964 items 
and 4,001,243 claims. In 2005, 52.07% of the items had higher reimbursement per 
unit in community pharmacy, 35.80% had higher reimbursement in mail-order phar-
macy and 13.31% had equal reimbursement. In 2005, estimated pharmaceutical 
expenditures of the comparison basket were $558.93 million using mail-order phar-
macy prices and $623.66 million using community pharmacy prices. This difference 
was attributed to higher reimbursement of ingredient cost, administrative fees and 
dispensing fees in community pharmacy. The difference in estimated pharmaceutical
expenditures of the comparison basket between community and mail-order pharmacy 
decreased from 12.8% in 2000 to 10.4% in 2005. Estimated pharmaceutical expen-
ditures in both channels increased from 2000–2005. The difference in total expendi-
tures, ingredient cost, dispensing, administration and other fees between channels 
decreased during the study period. CONCLUSIONS: Nearly one-half of all compara-
ble items had higher reimbursement per unit in community pharmacy than mail-order 
pharmacy. Overall expenditures were signiﬁ cantly lower in mail-order pharmacy.
Differences in pharmaceutical expenditures between community and mail-order phar-
macy were explained by differences in acquisition costs and fees. Decision makers 
should carefully evaluate pharmaceutical reimbursement including discounts, fees and
rebates when deciding the most efﬁ cient dispensing channel.
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OBJECTIVES: To evaluate and compare trends in design characteristics of brief-
summary formats of prescription drug print ads. METHODS: The source for these 
ads include a consumer magazine – National Geographic (NG) and three medical
journals – Annals of Internal Medicine (AIM), The Journal of the American Medical 
Association (JAMA) and The New England Journal of Medicine (NEJM). Each source
was visually reviewed by research assistants to record information from brief sum-
maries on ads from issues dated January 1, 2000 through December 31, 2004. The
design characteristics evaluated were text font size, font consistency, presence of 
bullets, highlights, tables, graphs, format type (e.g.: question/answer format), warning 
box, spacing between lines, and number of columns used to present the material. Font
size was measured using the Compugraphic scale. Data were coded and analyzed using
SAS 9.1. Descriptive statistics and comparisons using chi-square tests were per-
formed to evaluate differences by year and source at a priori signiﬁ cance level of 0.05.
RESULTS: A total of 7266 printed ads for 240 products manufactured by 90 phar-
maceutical companies were evaluated from NG (95), AIM (1372), JAMA (1787), and 
NEJM (4012) respectively. There were signiﬁ cant differences (p  0.05) in most design
characteristics by year (2000–2004), namely font consistency, presence of bullets,
highlights, tables, graphs, and warning box. These differences were also statistically
signiﬁ cant (p  0.05) across sources (magazine/journals). The question/answer format
and presence of a warning box was mostly seen in ads obtained from the magazine. 
The mean (SD) font size of the text on these ads was small (5.7 o 1.1) and consistent 
throughout these ads by year and source. CONCLUSIONS: Prescription drug print 
ads have changed over the years and are different based on the readership source.
Further improvement in standardizing the format and increasing the text font may 
help the intended readers of these ads.
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OBJECTIVES: Globalization necessitates better co-ordination among countries to
monitor disease outbreaks. The spread of SARS in 2003 highlights this need. Hence,
this study compared the notiﬁ able diseases surveillance websites of four countries. 
METHODS: Twenty-ﬁ ve countries were identiﬁ ed from literature that had published 
Human Development Index 0.9 and Quality-of-Life index 7. Four countries from 
this list were selected, namely, United States (US), Canada, Australia, and New 
Zealand. Fourteen European Union member countries were excluded, as they have a 
process to harmonize and consolidate their disease surveillance networks in place by 
